Search
BeiGene Prevails in US Patent Infringement Case, USPTO Invalidates Pharmacyclics' Patent
2025-04-30 /
Read about 0 minute
Author：小编
BeiGene has triumphantly announced that the United States Patent and Trademark Office (USPTO) has invalidated all claims of Pharmacyclics' '803 patent. Previously, Pharmacyclics had accused BeiGene's product, BRUKINSA®, of infringing upon this patent. In response, BeiGene vows to continue defending itself vigorously against any related patent infringement allegations.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
